Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(1012)
•••
Comment by investclubon Jan 08, 2020 8:41am
156 Views
Post# 30529633

RE:RE:RE:RE:RE:RE:RE:RE:There are a lot of posters on the board today--

RE:RE:RE:RE:RE:RE:RE:RE:There are a lot of posters on the board today--fredgoodwinson wrote

Perfectly reasonable proposition Endeavor but with the tone of yesterday`s Newsletter - which in itself gives them the option to bundle and delay what used to be individual intermittent NRs - my money is on this not happening.

Not because of any bad news,simply because this is the way that they want it to be right now.


Hi Fred 
I talked to Shushu yesterday she told me they wouldn't release results for the first 2 patients and even the first 5 was doubtful of a NR. Shushu said the company wanted to stay within the guidelines of other PH2 trials and only release results of significance such as 25 patients needed for fast track. The FDA IND approval would be news worthy along with new sites both sides of the border and enrollment plus those treated...  so everything will be released and only significant numbers of patient results not 2 not 5.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities